

Supplemental table 3. Clinical Characteristics of Groups 1 and 2.

	Etiology	Anatomy	flare (days)	AC cell grade*	Local Therapy**	Systemic Therapy
Group 1						
UV186	BSCR	PanU	365	0.5	0	none
UV143	JIA	AU	n/a	2	4	MTX, off ADA 1 week
UV195	VKH	PanU	60	1	3	40mg PDN, ADA for 1 w
UV165	Idiopathic	PanU	n/a	2	0	none
UV129	VKH	PanU	60	1	1	20mg PDN, MTX and AL
Group 2						
UV196	Idiopathic	AU_IU	7	2	4	none
UV019	HLA_B27	AU	9	3	8	none
UV213	Idiopathic	AU_IU	90	1	1	none
UV229	Idiopathic	PanU	90	2	2	hydroxychloroquine
UV150	Idiopathic	AU_IU	90	2	2	none
UV180	HLA_B27	AU	7	4	8	none
UV132	Idiopathic	AU	n/a	3	0	none
UV176	BSCR	PanU	30	3	0	none
UV160	Idiopathic	AU_IU	60	3	0	none
UV170	Idiopathic	PanU	8	2	4	none
UV215-03	Idiopathic	AU_IU	7	2	2	none
UV174	Idiopathic	AU_IU	30	3	0	none
UV284	Idiopathic	PanU	270	1	0	none
UV179	HLA_B27	AU	7	2	0	none
UV122	HLA_B27	AU	21	3	4	golimumab for 1 month
UV027	HLA_B27	AU	3	2	0	ADA 1 month, 30mg PD
UV031	Idiopathic	AU_IU	365	2	3	none

Key: **BSCR** Birdshot chorioretinitis; **JIA** juvenile idiopathic arthritis; **VKH** Vogt-Koyanagi Harada disease; **PanU** panuveitis; **AU** anterior uveitis, **AU_IU** anterior and intermediate uveitis; **AC** anterior chamber; *based on the Standardization in Uveitis Nomenclature (SUN) criteria; ** approximate topical steroid dose (i.e. number of drops prednisolone/day); **MTX** methotrexate; **ADA** adalimumab; **PDN** prednisone